MeSH D053202 - urge urinary incontinence
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Oxybutynin | Kentera (previously Oxybutynin Nicobrand) |  | 2004-06-15 |  |  |
| Solifenacin | Solifenacin |  | 2014-04-02 |  |  | |
| Padagis | Trospium | Trospium |  | 2010-11-17 |  |  |
| Glenmark Pharmaceuticals | Solifenacin | Solifenacin |  | 2019-05-20 |  |  |
| Trospium | Trospium |  | 2010-08-13 |  |  | |
| Xiromed | Darifenacin | Darifenacin |  | 2019-10-22 |  |  |
| Cipla | Darifenacin | Darifenacin |  | 2016-09-01 |  |  |
| Solifenacin | Solifenacin |  | 2019-05-20 |  |  | |
| Trospium | Trospium |  | 2016-08-23 |  |  | |
| Lupin Research | Mirabegron | Mirabegron |  | 2022-09-28 |  |  |
| Allergan | Trospium | Sanctura |  | 2004-05-28 |  |  |
| Fesoterodine | Fesoterodine |  | 2023-01-04 |  |  | |
| Solifenacin | Solifenacin |  | 2019-05-20 |  |  | |
| Trospium | Trospium |  | 2012-10-12 |  |  | |
| Pfizer | Fesoterodine | Toviaz | 2022-07-03 | 2008-10-31 | $146 M | Y2022 |
| Aurobindo Pharma | Darifenacin | Darifenacin |  | 2016-09-19 |  |  |
| Fesoterodine | Fesoterodine |  | 2017-02-17 |  |  | |
| Solifenacin | Solifenacin |  | 2022-12-27 |  |  | |
| Ajanta Pharma | Solifenacin | Solifenacin |  | 2019-05-20 |  |  |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
80%4/5
Phase 2
83%5/6
Phase 3
100%17/17
Approved: 9Overall Success rate: 67%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use